ANTI-GPT antibody produced in mouse

Serum GPT (Glutamate pyruvate transaminase 1) acts as a common biomarker in screening chronic liver injury. GPT levels identify the risk of osteoporosis in nonalcoholic fatty liver disease.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Glutamate-pyruvate transaminase (EC 2.6.1.2), also known as alanine aminotransferase, catalyzes the reversible conversion of L-alanine and alpha-ketoglutarate to L-glutamate and pyruvate. It has 2 distinct molecular and genetic forms: one cytoplasmic (soluble) (GPT1) and one mitochondrial (GPT2; MIM 138210). See ALTQTL1 (MIM 612363) and ALTQTL2 (MIM 612364) for information on quantitative trait loci influencing the plasma level of alanine aminotransferase.[supplied by OMIM

The GPT (glutamate pyruvate transaminase 1) gene with 11 exons spanning 2.7kb of genomic DNA, is mapped to human chromosome 8q24.3. The encoded protein consists of 495 amino acids and is identical to the human GPT-1.

GPT (AAH18207.1, 1 a.a. ~ 496 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence
MASSTGDRSQAVRHGLRAKVLTLDGMNPRVRRVEYAVRGPIVQRALELEQELRQGVKKPFTEVIRANIGDAQAMGQRPITFLRQVLALCVNPDLLSSPNFPDDAKKRAERILQACGGHSLGAYSVSSGIQLIREDVARYIERRDGGIPADPNNVFLSTGASDAIVTVLKLLVAGEGHTRTGVLIPIPQYPLYSATLAELGAVQVDYYLDEERAWALDVAELHRALGQARDHCRPRALCVINPGNPTGQVQTRECIEAVIRFAFEERLFLLADEVYQDNVYAAGSQFHSFKKVLMEMGPPYAGQQELASFHSTSKGYMGECGFRGGYVEVVNMDAAVQQQMLKLMSVRLCPPVPGQALLDLVVSPPAPTDPSFAQFQAEKQAVLAELAAKAKLTEQVFNEAPGISCNPVQGAMYSFPRVQLPPRAVERAQELGLAPDMFFCLRLLEETGICVVPGSGFGQREGTYHFRMTILPPLEKLRLLLEELSRFHAKFTLEYS

Solution in phosphate buffered saline, pH 7.4